

About

Sano Stemedica is a clinical-stage biotech company developing proprietary allogeneic cell therapy for critical health issues.

- Sanostemedica holds approximately 21 patents covering the technology composition of matter, disease indications, and large-scale manufacturing in key countries.
- We retain global rights to our technology, excluding China, where we have a single partner with licensing rights.
- Our stem cells have a unique, well characterized mechanism of action supported by more than 15 years of clinical and non clinical research with over 1200 patients dosed and a well tolerated safety profile



Clinical Focus

Ischemic Stroke Nearly 800,000 strokes per year in the US Leading cause of disability and third highest cause of death Over \$55 billion cost to the health care system annually Current standard of care reaches only 30% of patients We are starting Phase 2 B trial for stroke treatment in India.

Sanostem is a platform technology that can be used to address a number of indications with minor adjustments to dosing levels and administration routes. We have an expansive portfolio of earlier-stage opportunities that are built on the same technology platform, including indications such as Graft vs Host Disease, Multiple Sclerosis, and Traumatic Brain Injury.

Ischemic Stroke

- Nearly 800,000 strokes per year in the US
- Leading cause of disability and third highest cause of death
- Over \$55 billion cost to the health care system annually
- Current standard of care reaches only 30% of patients

Trauma

- Leading cause of death in people under 40 in the U.S.
- 30 million emergency department visits in the U.S. annually
- Cost to the US health care system of \$75 billion annually for car accidents, one subset of trauma
- Sanostem addresses complications that affect patients that survive the initial traumatic injury

ARDS

- 200,000 cases in the U.S. annually
- 30-50% mortality rate
- One of the leading causes of death in severe COVID-19 cases
- Notable burden to the health care system
- Few effective therapeutic modalities exist to ameliorate this deadly condition

Set up for Success

- New and experienced management team focused on execution and delivering results
- Lean operating structure dedicated to completing existing clinical trials and business development
- Actively pursuing development and commercialization partnerships to leverage non-core capabilities and secure non-dilutive capital

PLATFORM SUMMARY



Off-The-Shelf Product

Allogenic, no tissue matching, IV administration



Scalability, Stability & Consistent Product Quality

Single adult donor capable of generating hundreds of thousands of doses in proprietary process



Starting Phase 2 B cell therapy

Cell therapy study in ischemic stroke, safety data in >450 patients



Platform Technology: Opportunities Across Multiple High Value Indications

Clinical, IND-ready, & development stage immune, neurological & cardiopulmonary programs